Furthermore, a systematic understanding is lacking regarding the prevalence of PIK3CA mutations in HR+/HER2- advanced/unresectable or metastatic breast cancer or within clinically relevant molecular BC subgroups. Here, ERBB2 is linked to breast cancer.